WebIQ Pharma survey solution launched for pharmaceutical industry

NewsGuard 100/100 Score

Usability Sciences Corporation launches its WebIQ Pharma offering, an intelligent survey solution that provides pharmaceutical sites with metrics to answer critical questions about site and content effectiveness, to increase return on investment (ROI).  Usability Sciences has provided usability and user experience research to Merck (MRK), Eli Lilly (LLY), Novartis (NVS) and Ortho McNeil for over ten years.

Pharmaceutical brands build websites primarily to drive drug adoption. The brands want site visitors who have never tried the drug to make appointments with their doctors to discuss the drug. The brands want visitors who have been prescribed the drug to keep taking it and get their prescriptions refilled. Most importantly, the brands need to know which content areas drive the desired behaviors and which content areas do not.  Establishing the link between visitor response to the site and the content that determined their response has heretofore been extremely difficult. WebIQ Pharma makes it simple and, compared to the labor-intensive alternatives, extremely cost effective.

"WebIQ Pharma employs intelligent survey technology and intelligent dashboards in delivering this patented solution," said Usability Sciences President Jeff Schueler. "The intelligent survey technology allows the brand to ask questions of site visitors based on where they went on the site and what content they saw. WebIQ Pharma dashboards, rather than deliver more 'dumb' data, provide answers to the site's key business questions."

Usability Sciences developed the methodology specifically for the pharmaceutical industry, where brand sites often carry high costs but generate relatively low traffic. WebIQ Pharma arms the brand with a continuous stream of answers to drug adoption questions and allows them to constantly improve site stickiness, conversion, and ROI. WebIQ Pharma is flexible and can be customized to fit any brand's needs and preferences in terms of options and pricing.

SOURCE Usability Sciences Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Extended CPAP treatment boosts lung development in premature infants